Use of lopinavir/ritonavir in HIV-infected patients failing a first-line protease-inhibitor-containing HAART | Zendy

Marco Bongiovanni | Zendy; Elisabetta Chiesa | Zendy; Antonio Di Biagio | Zendy; Paola Meraviglia | Zendy; Amedeo Capetti | Zendy; Federica Tordato | Zendy; Paola Cicconi | Zendy; Patrizia Biasi | Zendy; Teresa Bini | Zendy; Antonella d’Arminio Monforte | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Use of lopinavir/ritonavir in HIV-infected patients failing a first-line protease-inhibitor-containing HAART

Author(s) -

Marco Bongiovanni,

Elisabetta Chiesa,

Antonio Di Biagio,

Paola Meraviglia,

Amedeo Capetti,

Federica Tordato,

Paola Cicconi,

Patrizia Biasi,

Teresa Bini,

Antonella d’Arminio Monforte

Publication year - 2005

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dki113

Subject(s) - lopinavir , ritonavir , lopinavir/ritonavir , protease inhibitor (pharmacology) , medicine , virology , human immunodeficiency virus (hiv) , pharmacology , viral load , antiretroviral therapy

The long-term virological efficacy of lopinavir/ritonavir-containing highly active antiretroviral therapy (HAART) in HIV-infected patients failing a first-line protease inhibitor (PI)-based regimen is still unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research